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INTRODUCTION
Acute graft-versus-host disease (aGVHD) remains a
major determinant of the morbidity and mortality associated
with allogeneic bone marrow transplantation. Approxi-
mately 40% to 55% of patients undergoing an allogeneic
marrow transplant will develop aGVHD [1-3]; the incidence
is even greater after a transplant from an unrelated or mis-
matched donor. Despite major advances in the understand-
ing of the pathophysiology governing aGVHD and the
development of more targeted immunosuppressive therapies
with monoclonal antibodies directed against T cells, lym-
phoblasts, cytokines, and cytokine receptors [4-9], cortico-
steroids remain the front-line approach to therapy [10].
Therapy with glucocorticoids is suboptimal, with con-
tinuing complete response rates of 41% in histocompatible
sibling allogeneic transplant recipients [1]. Response in
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ABSTRACT
Glucocorticoids remain the standard approach to initial systemic management of acute graft-versus-host disease
(aGVHD). For patients refractory to steroids, antithymocyte globulin (ATG) is frequently used as salvage therapy.
We decided to test whether the combination of corticosteroids and equine ATG would improve the outcome of initial
management of aGVHD, especially in high-risk patients such as recipients of unrelated donor (URD) transplants.
One hundred patients with grade II to IV aGVHD having undergone a related or URD marrow transplant were
enrolled in the study. Of the patients, 46 were randomly assigned to therapy with prednisone (60 mg/m2 per day × 7 days)
and 50 received ATG/prednisone (15 mg/kg ATG bid plus 20 mg/m2 prednisone bid × 5 days, each followed by an
8-week prednisone taper). An intent-to-treat analysis of the overall response at day 42 revealed equivalent complete
plus partial response rates of 76% in both the prednisone and ATG/prednisone therapy groups (P > .80). In univariate
analysis, patient age, donor type, site of involvement, or aGVHD stage did not influence overall response to therapy
(all P > .2). When treatment arms were studied separately, no single clinical feature predicted outcome in either
group. Complications were more frequent in the ATG/prednisone arm; patients experienced more infections with
cytomegalovirus (44% versus 22%; P = .02) and more frequent pneumonitis, both infectious and noninfectious (50%
versus 24%; P < .01). Epstein-Barr virus lymphoproliferative disease was uncommon (4 cases) and comparable in both
arms (P = .35). There was no significant difference in survival at day 100, 6 months, and 2 years between the 2 treat-
ment arms. The more intensive immunosuppressive combination of ATG/prednisone failed to improve control of
aGVHD and may have affected survival by causing more infectious complications. Combination therapy with ATG
should thus be reserved as second-line therapy in the management of aGVHD.
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unrelated donor (URD) transplant recipients is even more
disappointing, with only 24% of patients showing improve-
ment after therapy with corticosteroids [2]. Liver and multi-
organ involvement has been shown to be associated with a
poor response to steroid therapy [1]. Secondary treatment is
often required for patients who fail to achieve an adequate
response to steroids. Antithymocyte globulin (ATG) is fre-
quently included in secondary therapy. Improvement or dis-
ease stabilization is seen in 55% of patients receiving ATG
as second-line therapy [11,12]. There is some suggestion
that intensive therapy earlier in the course of the disease
results in improved response rates [1]. This therapy would
be especially important in high-risk patients, including
recipients of URD marrow transplants.
We therefore performed a randomized controlled clini-
cal trial testing the value of more intensive front-line
immunosuppressive therapy for aGVHD using the combi-
nation of ATG plus prednisone and comparing it with pred-
nisone alone. Although ATG had been evaluated some years
earlier as initial therapy for aGVHD [13], we performed this
study to test whether a subgroup of patients with more
aggressive disease, especially those with unrelated donors,
might benefit from this combination. The results of this
randomized trial including both sibling donor and URD
bone marrow transplants are reported herein.
MATERIALS AND METHODS
Study Design
In a single-center, randomized, open-label trial, we com-
pared ATG/prednisone to prednisone alone as initial therapy
for aGVHD. All patients with moderately severe aGVHD
(clinical grade II to IV; see below) having received an allo-
geneic bone marrow transplantation within the last 120 days
were eligible. Patients with mild (grade I) aGVHD were eli-
gible if they failed to improve after a minimum of 7 to 10 days
of topical steroids. Patients or their guardians were required
to give informed consent to randomization and therapy using
consent forms reviewed and approved by the University of
Minnesota Institutional Review Board. Eligible consenting
patients were randomly assigned (1:1) to either treatment
arm. To assure balance within the 2 treatment cohorts (pred-
nisone alone versus ATG/prednisone), before randomization,
patients were stratiﬁed by age (≤18 years versus >18 years)
and transplant type (related versus unrelated donor).
Diagnosis and Staging of aGVHD
The diagnosis of aGVHD was made clinically with his-
tological confirmation whenever possible. Patients were
staged both according to the Seattle clinical staging and
grading system, modiﬁed to include upper gastrointestinal
(GI) aGVHD per the GVHD consensus conference [14,15]
and the GVHD stage scoring system [1,14]. This latter sys-
tem is based on the sum of each aGVHD organ stage using
the consensus clinical staging [15] plus 1 point for histologi-
cally proven upper-GI GVHD, thus producing a scoring
range of 0 to 13 (0 to 4 for skin, liver, and lower GI, and
1 for upper GI). Moderately severe aGVHD was deﬁned as
clinical grade II to III or GVHD stage score of 3 to 11.
Clinical grade I, or limited skin involvement, and stages 1 to
2 were considered mild aGVHD.
Treatment
Patients randomized to the prednisone arm were given
the equivalent of 60 mg/m2 per day prednisone (orally or
intravenously) in 3 divided doses for 7 days followed by a
single dose for 7 days and a rapid taper over 8 weeks [16].
Patients assigned to ATG/prednisone received the equiva-
lent of 60 mg/m2 prednisone in 2 divided doses (as premed-
ication for ATG) plus 15 mg/kg equine ATG (Upjohn,
Kalamazoo, MI) intravenously over 3 hours every 12 hours
for 5 days. Generally, diphenhydramine (25 to 50 mg intra-
venously) was added to the prednisone as a premedication
for ATG, and for the ﬁrst dose only, 1 mL of the ATG infu-
sion was given intravenously, and the patient was observed
for 30 minutes before infusion of the remaining ATG. This
step was followed by 60 mg/m2 per day prednisone for 7 days
with a subsequent taper over 8 weeks. All patients with skin
involvement received 0.1% topical triamcinolone to affected
areas 3 times a day (1% hydrocortisone to the face).
Patients with no improvement within 7 days or having
progression within 4 days were allowed to cross over to the
ATG/prednisone arm or were re-treated with a second
course of ATG/prednisone. During tapering of pred-
nisone, if a flare-up of aGVHD developed, the dose of
prednisone was increased by 20 mg/m2 per day. This dose
was maintained for 14 days; if at the end of this period an
improvement was documented, the taper of prednisone was
resumed. Patients with severe or progressive aGVHD (as
deﬁned by one of the following: grade IV aGVHD at diag-
nosis, progression of aGVHD on therapy, lack of improve-
ment after 2 courses of initial therapy, or second signiﬁcant
ﬂare-up after prednisone taper) were treated with 1.5 mg/kg
cyclosporine intravenously every 12 hours and 250 mg/m2
methylprednisolone and 15 mg/kg ATG, both intravenously,
twice a day for 5 days. After 5 days, 60 mg/m2 prednisone
was given daily for 7 days and then tapered slowly over
12 weeks. For all patients, cyclosporine was continued until
1 month after completion of prednisone and was then
tapered by 5% per week.
Cyclosporine was given as GVHD prophylaxis to 61
(53%) of the patients enrolled in the trial (Table 1). It was con-
tinued after the diagnosis of aGVHD and throughout therapy.
Patients received deﬁned supportive care, which included con-
tinuing prophylaxis for bacterial infections (250 mg penicillin
VK [penicillin V potassium] po, bid) and fungal infections
(clotrimazole, nystatin, or ﬂuconazole), pneumocystis carinii
pneumonia (trimethoprim-sulfa double-strength bid every
Monday and Tuesday), and cytomegalovirus (CMV) (800 mg
acyclovir po 5 times per day).
Evaluation of Therapeutic Response
Response to therapy was evaluated by the attending
physician of the bone marrow transplantation (BMT) ser-
vice and prospectively recorded in the University of Min-
nesota BMT Database at treatment days 7, 14, 21, 28, and
42 by determining the GVHD clinical stage score for each
time point (±3 days) [3]. Complete response (CR) was
deﬁned as resolution of all symptoms in all organs. Partial
response (PR) was defined as improvement in ≥1 organ
without any worsening in other organs. Stable disease (SD)
was deﬁned as no change in any organ system. Improvement
in ≥1 organ with deterioration in ≥1 organ was designated as
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a mixed response (MR). Progression was deﬁned as worsen-
ing GVHD in ≥1 organ without amelioration in any organ.
The summary response to initial therapy was assessed at
the latest evaluation between treatment days 28 and 42. Sta-
ble disease, mixed response, progression, and failure of pri-
mary therapy that necessitated an additional course or a
change in course of therapy were designated as treatment
failure. Patients could not be evaluated if not graded at day
42 (±7 days), and a score could not be inferred from avail-
able data (ie, the same score before and after day 42 without
any interim change in therapy). In the event of chronic
GVHD or death, patients were then subsequently censored
as not evaluable because of their response to aGVHD ther-
apy. The overall response, both by individual organ site and
overall, was also determined at day 42. This assessment eval-
uated the overall response to therapy within an initially
assigned treatment arm without considering additional ther-
apy or change in therapy as treatment failure. Thus, this
overall response assessment represented a comparative
analysis by intention to treat. Patients were scored as CR,
PR, MR, SD, progression, or chronic GVHD.
Assessment of End Points
The primary end points were assessment of response to
initial therapy and overall response. In addition, patients’
responses were determined by stratiﬁcation cohorts of age,
type of transplant, and site of involvement to determine
whether any subgroup in particular could benefit from
more aggressive treatment with ATG/prednisone. Sec-
ondary end points included survival, complications from
therapy, and cause of death.
Statistics
To compare the distribution of baseline characteristics
across randomized treatment groups, Pearson’s chi-square
test was used for categorical variables, and the general
Wilcoxon test was used for continuous variables [17].
Univariate comparisons of the primary end points were
evaluated with Pearson’s chi-square test. Investigation of
potential confounding and interactions between the ran-
domized groups and the study end points was performed
with chi-square tests and logistic regression. Factors tested
included age, conditioning regimen, type of donor, HLA-
matching status, sex mismatch, GVHD prophylaxis, baseline
GVHD grade and state, and organ involvement.
Survival was estimated by the Kaplan-Meier method
[18]. Statistical comparisons of the Kaplan-Meier curves
were completed by use of the log rank test.
RESULTS
Patient Characteristics
One hundred patients were enrolled in the study. Of the
patients, 50 were treated with ATG/prednisone and
46 received prednisone alone; 4 were excluded from analysis
after randomization because biopsies of suspected involved
organs failed to conﬁrm the diagnosis of aGVHD. Patients
with aGVHD not enrolled in the study were treated with
prednisone alone, according to our institutional standard of
care. Reasons for exclusion from the study included both
patient and physician preferences. Some patients were reluc-
tant to be rehospitalized for therapy with ATG, and some
physicians were concerned about the increased myelosup-
pression, possible infections, and lymphoproliferative dis-
ease risks associated with ATG.
Table 1. Patient Characteristics*
ATG/
Prednisone Prednisone P
n 50 46 —
Age, y
0-9 15 (30) 15 (33) .38
10-19 9 (18) 7 (15)
20-29 7 (14) 2 (4)
30-39 9 (18) 14 (31)
40-51 10 (20) 8 (17)
Median (range) 23 (1-51) 28 (1-51) .64†
Sex
Male 31 (62) 33 (72) .31
Female 19 (38) 13 (28)
Diagnosis at transplant
Acute leukemia 22 (44) 16 (35) >.80
CML 18 (36) 16 (35)
Other malignancies 3 (6) 5 (11)
Aplastic anemia 1 (2) 2 (4)
Immune deficiencies 2 (4) 3 (6)
Metabolic disorders 4 (8) 4 (9)
High-risk leukemia‡ 28 (56) 17 (37) .44
Low-risk leukemia§ 15 (30) 20 (44)
Conditioning regimens
CY/TBI 37 (74) 36 (78) .55
Other 13 (26) 10 (22)
GVHD prophylaxis
MC 27 (54) 24 (52) .24
MAP 11 (22) 12 (26)
Other 12 (24) 10 (22)
Transplant type
Matched related (sibling) 21 (42) 23 (50) .29
Related other 2 (4) 1 (2)
Matched unrelated 7 (14) 11 (24)
Mismatched unrelated 20 (40) 11 (24)
Donors
Sex matched 23 (46) 25 (54) .41
Sex mismatched 27 (54) 21 (46)
CMV serology
Recipient positive 28 (57) 21 (46) .42
Recipient negative, donor positive 8 (16) 6 (13)
Recipient negative, donor negative 14 (29) 19 (41)
*Data are n (%) or median (range). ATG indicates antithymocyte globu-
lin; CML, chronic myelogenous leukemia; CY/TBI, cyclophosphamide
and total body irradiation; GVHD, graft-versus-host disease; MC,
methotrexate and cyclosporine; MAP, methotrexate, ATG, and pred-
nisone; CMV, cytomegalovirus.
†Analyzed by general Wilcoxon test.
‡Low-risk leukemia was deﬁned as acute lymphoblastic leukemia in ﬁrst
and second complete remission, acute myelogenous leukemia in first
remission, and chronic myelogenous leukemia in chronic phase.
§All other leukemias and myelodysplastic syndromes were considered
high risk.
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Characteristics of the study population are shown in
Table 1. Patient diagnoses were categorized into risk
groups. Low-risk leukemia was defined as acute lym-
phoblastic leukemia in first and second complete remis-
sion, acute myelogenous leukemia in first remission, and
chronic myelogenous leukemia in chronic phase; all other
leukemias and myelodysplastic syndrome were consid-
ered high risk. The patient baseline characteristics in the
2 treatment cohorts were comparable except for somewhat
more frequent diagnoses of high-risk leukemia and more
mismatched unrelated transplants among patients treated
with ATG/prednisone.
Characteristics of aGVHD at Study Entry
The diagnosis of aGVHD was confirmed by biopsy
when possible; 92% of skin, 7% of liver, 72% of lower GI,
and 100% of upper GI aGVHD diagnoses were proven his-
tologically. Characteristics of the patients’ aGVHD at time
of study entry are shown in Table 2. The severity and extent
of aGVHD at diagnosis were similar in both treatment arms.
Response to Therapy
Response to initial therapy and overall response to
therapy at day 42 are presented in Table 3. Despite its lesser
immunosuppressive potency, initial therapy with pred-
nisone alone yielded a higher complete and partial response
rate than therapy with ATG/prednisone (55% CR/PR com-
pared with 27%, P = .02). However, an intent-to-treat
analysis including both the initially randomized treatment
and any subsequent therapy yielded an equivalent overall
response rate at day 42 in both therapy groups. Seventeen
patients randomized to prednisone alone received sec-
ondary therapy with ATG/prednisone from day 4 to day 95
after initiation of primary therapy (median 10 days),
whereas 22 patients initially treated with ATG/prednisone
received a second course between day 4 and day 42 (median
13 days). Overall complete plus partial response rates of
76% in both the prednisone and ATG/prednisone treat-
ment groups were observed (P > .80).
Overall response by organ site was also evaluated. In
both the skin and gastrointestinal tract, response to either
prednisone or ATG/prednisone led to similar response rates
(skin: 71% CR/PR for prednisone versus 79% for ATG/pred-
nisone; GI tract: 75% CR/PR for prednisone versus 82%
for ATG/prednisone). Although more patients with liver
involvement achieved a complete or partial response to
prednisone alone (5 of 7 patients) compared with ATG/pred-
nisone (2 of 6 patients), this result did not attain statistical
signiﬁcance (P = .29).
Clinical Features Associated With Overall Response
to Therapy
In the entire group, several clinical features were
assessed as to their inﬂuence on the overall response rate. In
univariate analysis, patient age, donor type, prior GVHD
prophylaxis, or site of involvement by aGVDH did not
inﬂuence the overall response (all P > .27, data not shown).
aGVHD stage, determined by either a clinical grade or a
stage scoring system, did not predict overall response to
therapy (P > .45, data not shown).
These same clinical features were examined for any
inﬂuence on overall response rate between the 2 treatment
arms (Table 4). Neither treatment arm was shown to be
superior within various subgroups of the study population.
Patients undergoing an unrelated mismatched donor trans-
plantation faired similarly well when treated with either
ATG/prednisone or prednisone (CR + PR 74% versus 90%,
P = .27). This was also apparent in patients with more severe
(stage score 2 to 6) aGVHD at diagnosis (CR + PR 76%
versus 78%, P = .63). Although patients with multi-organ
involvement had a higher complete and partial response to
ATG/prednisone (82% versus 67%), this difference failed to
reach statistical signiﬁcance (P = .14).
Table 2. Characteristics of Acute Graft-Versus-Host Disease at Study Entry*
ATG/
Prednisone Prednisone P
Day of diagnosis 25 (10-85) 27 (8-72) >.80†
Day of treatment 31 (10-89) 30 (8-74) .37†
Clinical grade‡
I 12 (24) 10 (22) >.80
II 35 (70) 34 (74)
III 3 (6) 2 (4)
aGVHD stage score§
1 6 (12) 4 (9) >.80
2 14 (28) 17 (37)
3 21 (42) 18 (39)
4 3 (6) 4 (9)
5 3 (6) 2 (4)
6 3 (6) 1 (2)
Organ involvement
Skin only 29 (58) 21 (46) .48
Liver only 0 0
GI only 4 (8) 5 (11)
Multi-organ 17 (34) 20 (43)
*Data are median (range) or n (%). ATG indicates antithymocyte globu-
lin; aGVHD, acute graft-versus-host disease; GI, gastrointestinal.
†Analyzed by Wilcoxon 2-sample test.
‡Per the GVHD consensus grading scale [1,14,15].
§The sum of each organ stage (0-4) ± 1 for histologically proven upper
GI aGVHD.
Table 3. Response to Acute Graft-Versus-Host Disease Therapy*
Response to ATG/
Initial Therapy† Prednisone Prednisone P
Complete/partial response 10 (27) 18 (55) .02
Treatment failure 27 (73) 15 (45)
Overall response at day 42‡
Complete/partial response 34 (76) 32 (76) >.80
Failure to achieve complete 11 (24) 10 (24)
or partial response
*Data are n (%).  ATG indicates antithymocyte globulin.
†Initial response reﬂects best sustained response to initially randomized
therapy. Crossover or retreatment is scored as treatment failure.
‡Overall response reflects final best response of randomized therapy
(analyzed by intention to treat), and secondary aGVHD therapy is not
scored as treatment failure.
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Complications of Therapy for aGVDH
Complications deriving from the immunosuppressive
effects of both treatment arms were examined. Among
patients at risk, those randomized to receive ATG/pred-
nisone developed CMV infections (viremia documented by
shell vial assay or organ disease) more frequently (44% ver-
sus 22%, P = .02). Somewhat more frequent gram-negative
infections were seen among patients initially treated with
ATG/prednisone (40% versus 24%, P = .14). These gram-
negative infections also tended to occur earlier, with a
median time to ﬁrst infection of 46 days (range, 0-124 days)
from the onset of aGVHD therapy compared with 70 days
(range, 7-116 days) for patients receiving prednisone alone.
There was no difference in the incidence of fungal infec-
tions, including both Candida and Aspergillus, among the
2 groups. Among the patients treated with ATG/prednisone,
there were 4 Candida and 3 Aspergillus infections (7 of 50)
compared with 2 Candida and 1 Aspergillus infections (3 of
46) in the prednisone cohort (P = .23). Pneumonitis occurred
more commonly among patients in the ATG/prednisone arm
(50% versus 24%, P < .01), including pulmonary syndromes
deﬁned as infectious based on pathology, microbiology, and
virology from bronchoalveolar lavage and noninfectious
pneumonitis where such studies excluded infectious
pathogens. The incidence of Epstein-Barr virus (EBV) lym-
phoproliferative disease was low and was comparable in both
arms: 3 patients (6%) receiving ATG/prednisone developed
an EBV lymphoma at days 42, 69, and 85 of therapy versus
only 1 (2%) receiving prednisone at day 93 (P = .35). The
incidence of chronic GVHD was similar in both groups.
ATG/prednisone–treated patients had a 6-month incidence
of 64% (95% conﬁdence interval [CI], 47% to 81%) com-
pared with the prednisone group, who had a 6-month inci-
dence of 50% (34% to 66%; not signiﬁcant [NS]).
Survival
Overall survival was determined at 100 days, 6 months,
and 2 years (Table 5 and Figure). After a median follow-up of
48 months (range, 23-68 months), there was no difference in
overall survival between the 2 treatment arms, although a
modest statistical trend toward improved survival was seen
within the ﬁrst 3 and 6 months for patients treated with pred-
nisone alone. Beyond 6 months, the plots of survival shown in
the Figure are relatively parallel. A multiple regression analy-
sis failed to demonstrate any confounding pretransplant fac-
tors, including age, diagnosis, conditioning regimen, type of
transplant, HLA donor match, GVHD prophylaxis, aGVHD
stage, and organ involvement, that modiﬁed the randomized
therapies’ effect on survival (data not shown). The treatment
arm had no signiﬁcant impact on overall survival. In a subset
Table 4. Clinical Features Associated With the Overall Response to Therapy*
ATG/Prednisone Prednisone P
n CR + PR (%) n CR + PR (%)
Age, y
<18 19 15 (79) 19 16 (84) .62
≥18 26 19 (73) 23 16 (70)
Conditioning regimen
CY/TBI 33 25 (76) 34 26 (76) >.80
Other 12 9 (75) 8 6 (75)
Transplant type
Related 21 17 (81) 22 16 (73) .35
Unrelated 34 17 (71) 20 16 (80)
HLA match
URD MM 19 14 (74) 10 9 (90) .27
Other 26 20 (77) 32 23 (72)
Donor recipient sex
Match 22 16 (73) 23 18 (78) .58
Mismatch 23 18 (78) 19 14 (74)
GVHD prophylaxis
CSA + MTX 24 18 (75) 22 18 (82) .48
Other 21 16 (76) 20 14 (70)
Acute GVHD clinical grade
I 9 6 (67) 9 8 (89) .21
II-III 36 28 (78) 33 24 (73)
Acute GVHD stage score
1 5 3 (60) 4 3 (75) .63
2-6 40 31 (78) 38 29 (76)
Skin involvement only
Yes 25 18 (72) 19 16 (84) .22
No 20 16 (80) 23 16 (70)
Multi-organ involvement
Yes 17 14 (82) 18 12 (67) .14
No 28 20 (71) 24 20 (83)
*ATG indicates antithymocyte globulin; CR, complete response; PR, partial response; CY/TBI, cyclophosphamide and total body irradiation; URD
MM, unrelated mismatched donor; CSA + MTX, cyclosporine and methotrexate; GVHD, graft-versus-host disease.
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analysis of patients undergoing mismatched unrelated donor
transplant, 6-month survival remained comparable in both
arms: prednisone 45% (95% CI 30% to 60%) and ATG/pred-
nisone 35% (14% to 56%) (NS).
In an additional analysis, we examined possible factors
affecting overall survival at 6 months. Gram-negative infec-
tions (overall survival for those with a gram-negative infection
42% versus 63% for those without; P = .06) and fungal infec-
tions (overall survival 17% versus 62%; P < .01) were associ-
ated with an expected negative impact on survival. Pneumoni-
tis, both infectious and noninfectious, also carried a worse
prognosis (6-month survival 24% and 47%, respectively, ver-
sus 70% for those without pneumonitis; P < .01). Interestingly,
the severity of aGVHD at diagnosis did not affect survival.
Somewhat surprisingly, patients with multiorgan involvement
had survival similar to that of patients with aGVHD limited
either to the skin or to the gastrointestinal tract (6-month sur-
vival 57% versus 54% and 67%, respectively; P > .80). Overall
response to therapy of aGVHD did not lead to better survival.
Six-month survival for patients achieving a complete and par-
tial response to therapy was 58% compared with 71% for
patients achieving a lesser response (P = .27).
Clinically attributable causes of death were similar in
both groups. Of those randomized to ATG, 2 deaths were
due to malignant relapse, 3 to secondary malignancy and
GVHD, and 24 to GVHD complicated by infection and/or
pneumonitis. Of the prednisone-assigned patients, 6 deaths
were due to relapse, 1 to secondary malignancy, and 15 to
GVHD and complications.
DISCUSSION
aGVHD is mediated by the activation of mature donor
T cells in response to foreign recipient major and minor his-
tocompatibility antigens [19,20]. This recognition leads to
the activation of inﬂammatory effector cells and cytokines,
resulting in organ damage involving the skin, gastrointesti-
nal tract, liver, and immune system [21,22]. Therapy for
established aGVHD aims at abrogating this immune
response either by targeting T cells or, more speciﬁcally, by
targeting effector cells and elaborated cytokines. Glucocor-
ticoids are probably beneﬁcial because of their lympholytic
effect. They also prevent antigen-presenting cell synthesis
of interleukin-1 [23]. ATG is a polyclonal antibody prepara-
tion whose active component is difficult to isolate. It has
been postulated to act by exerting an inhibitory effect on
donor T cells, recipient lymphoid tissue, or both [24,25].
We hypothesized that the enhanced immunosuppression
obtained from the combination of prednisone and ATG
would lead to a greater control of aGVHD, especially in
subgroups expected to have a poor prognosis. This prospec-
tively evaluated randomized trial showed no advantage in
either response rates or survival after addition of ATG to
the initial therapy of aGVHD.
Evaluation of the overall response to therapy by an
intent-to-treat analysis showed that the combination of
ATG and prednisone was equivalent to prednisone alone.
Both groups achieved a 76% complete and partial response
rate to therapy. Response to treatment within the organ site
of involvement was also similar. Of the clinical features ana-
lyzed, including patient age, donor type, and site of involve-
ment, none were associated with a superior response rate,
either in the group as a whole or within the randomized
treatment arms. Although we and others have previously
found the severity of aGVHD at the time of initial therapy
to inﬂuence the response rate [1,3,10], this association was
not observed in the present study. The more intense
immunosuppression from ATG/prednisone did not improve
the outcome in unrelated mismatched transplant donor
recipients. A higher response rate was seen in patients with
multi-organ involvement treated with ATG/prednisone
(82% versus 67%) but failed to reach statistical signiﬁcance
(P = .14). A similar prospective trial in a matched sibling
donor BMT evaluating a CD5-ricin A chain immunotoxin
added to prednisone also showed no net beneﬁt to the more
intense immunosuppressive therapy of aGVHD [26].
Complications secondary to therapy occurred more fre-
quently in the ATG/prednisone arm. The enhanced
immunosuppression associated with ATG/prednisone led to
an increased incidence of infections—particularly CMV and
gram-negative infections. Pneumonitis, both infectious and
noninfectious, was also more commonly observed. The
addition of methylprednisone to the combination of ATG
and cyclosporin A for the management of aGVHD has pre-
viously been reported to result in more frequent infectious
complications [27]. Although some preparations of ATG
(especially those used for in vivo T-cell depletion to pro-
mote engraftment) have been reported to contribute to the
development of EBV-associated B-cell lymphoproliferative
Table 5. Overall Survival*
ATG/Prednisone Prednisone P
n 50 46 —
100-day survival 60 (46-74) 78 (66-90) .10
6-month survival 48 (34-62) 65 (51-79) .10
2-year survival 40 (26-54) 50 (36-64) .21
*Data are % (95% conﬁdence interval) or n. ATG indicates antithymo-
cyte globulin.
Two-year survival curve for patients with moderately severe acute graft-ver-
sus-host disease. Initial therapy with either prednisone or antithymocyte
globulin (ATG)/prednisone yielded similar survival rates (P = .21).
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disease [28], these lymphoproliferative disorders were
uncommon in both therapy groups.
Although overall survival between the 2 treatment
groups was similar, there was a trend toward improved sur-
vival within the ﬁrst 6 months in the prednisone arm. This
trend was in part due to the increased incidence of early
infections and pneumonitis seen in patients treated with the
ATG/prednisone combination. In the subgroup analysis,
ATG/prednisone failed to improve the outcome for patients
anticipated to have the highest risk—those undergoing mis-
matched unrelated donor transplants. Surprisingly, neither
the initial severity of aGVHD nor the overall response to
therapy predicts a better survival.
The results of the present randomized trial do not sup-
port the use of ATG/prednisone as initial therapy in the
treatment of aGVHD. The increased immunosuppression
associated with the ATG/prednisone combination failed to
improve control of aGVHD, both for the group as a whole
and for the subgroup of patients undergoing an unrelated
donor transplant. In fact, ATG/prednisone may compromise
early survival because of increased infectious complications.
Many patients in the present study received successful sec-
ondary therapy with ATG/prednisone after initial therapy
with prednisone alone failed. It is most appropriate, there-
fore, to reserve combination therapy with ATG for second-
line use in the management of aGVHD.
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